Acute myelogenous leukemia (AML) is a high-risk hematopoietic malignancy caused by a variety of mutations, including genes encoding the cohesin complex. Recent studies have demonstrated that reduction in cohesin complex levels leads to enhanced selfrenewal in hematopoietic stem and progenitors (HSPCs). We sought to delineate the molecular mechanisms by which cohesin mutations promote enhanced HSPC self-renewal as this represents a critical initial step during leukemic transformation. We verified that RNAi against the cohesin subunit Rad21 causes enhanced self-renewal of HSPCs in vitro through derepression of polycomb repressive complex 2 (PRC2) target genes, including Hoxa7 and Hoxa9. Importantly, knockdown of either Hoxa7 or Hoxa9 suppressed self-renewal, implying that both are critical downstream effectors of reduced cohesin levels. We further demonstrate that the cohesin and PRC2 complexes interact and are bound in close proximity to Hoxa7 and Hoxa9. Rad21 depletion resulted in decreased levels of H3K27me3 at the Hoxa7 and Hoxa9 promoters, consistent with Rad21 being critical to proper gene silencing by recruiting the PRC2 complex. Our data demonstrates that the cohesin complex regulates PRC2 targeting to silence Hoxa7 and Hoxa9 and negatively regulate self-renewal. Our studies identify a novel epigenetic mechanism underlying leukemogenesis in AML patients with cohesin mutations.
INTRODUCTION
Acute myelogenous leukemia (AML) is an aggressive myeloid malignancy. 1, 2 Even when patients are treated with highly intense chemotherapy regimens, including consolidation with allogeneic bone marrow transplantation, long-term survival rates remain poor. The cause of this poor prognosis for patients with AML is multifactorial. One common finding hindering the development of novel therapeutics is high genetic variability among patients. 3 A subset of patients have recurrent chromosomal translocations, which generate driver oncogenic fusion proteins such as RUNX1-RUNX1T1 or MYH11-CBFB; 3 however, the majority of patients do not have a clear structural abnormality driving their leukemia. Many karyotypically normal AML patients have mutations in genes, including FLT3, TET2, NPM1, CEBPA or DNMT3A. A study in which 200 patients with de novo AML were sequenced 3 revealed that patients have on average 13 distinct somatic mutations within the coding regions of 4250 well-annotated genes, indicating AML arises from a diverse combination of mutations. A subset of the genes uncovered were not previously described in AML patients including subunits of the cohesin complex (RAD21, STAG2, SMC1A, SMC3). [3] [4] [5] [6] [7] Cohesin mutations tend to occur early within disease pathogenesis, 3, 6 implying that these mutations are critical events during leukemia development. Subsequent studies have confirmed that cohesin mutations are relatively common in AML and frequently co-occur with known driver mutations, including NPM1 and FLT3-internal tandem duplication (ITD). 3, 4, [6] [7] [8] Complete loss of cohesin function causes an embryonic lethal phenotype in knockout mice, implying that some level of cohesin function is absolutely required for normal development. [9] [10] [11] [12] Interestingly, somatic cohesin mutations in AML are uniformly heterozygous and not associated with dramatic changes in chromosomal number, implying that cohesin mutations promote AML through a function independent of their role during mitosis. 3, 6, 7, 13, 14 Cohesin has a critical role in controlling gene expression. 13, 15, 16 The complex facilitates DNA looping that permits interactions between distal genomic segments and gene promoters facilitating transcriptional regulation in cis. [17] [18] [19] The cohesin complex interacts with CCCTC-binding factor (CTCF) to organize the genome and recruit cis-regulatory elements, which promote gene silencing. 17, [20] [21] [22] Given the importance of transcriptional regulators in the pathogenesis of AML, 3 it has been hypothesized that cohesin mutations promote AML through altered gene expression.
Recent studies demonstrate that reduced cohesin expression confers enhanced self-renewal on hematopoietic stem and progenitor cells (HSPCs) both in vitro and in vivo. [23] [24] [25] [26] These studies demonstrated that reducing expression of single cohesin genes induces genome-wide changes in chromatin accessibility, and when combined with Flt3-ITD mutations, it resulted in potentiated signal transducer and activator of transcription factor 5 signaling and 100% penetrant leukemia with an average latency of 6 months. 24 Other studies observed altered numbers of higherorder HSPCs (short-term or long-term hematopoietic stem cells (LT-and ST-HSCs, respectively)) in vivo, after prolonged cohesin depletion, [23] [24] [25] whereas more differentiated progenitor populations (common myeloid progenitor, granulocyte macrophage progenitor, megakaryocyte erythrocyte progenitor) remained unchanged. 23, 25 Prolonged cohesin depletion causes increased HSPC self-renewal, a potential mechanism to leukemic transformation. 23, 26 Thus, although multiple groups have demonstrated cohesin mutations promote enhanced HSPC self-renewal and altered gene expression, the precise molecular mechanism connecting cohesin depletion to these changes remains unclear.
MATERIALS AND METHODS
A detailed Materials and methods section can be found in the Supplementary Material.
RESULTS

Rad21 depletion augments self-renewal and proliferation of murine HSPCs in vitro
Rad21 is a critical component of the cohesin complex, and to define its role in normal hematopoiesis in vitro, we transduced murine HSPCs with puromycin resistance encoding lentiviruses containing two independent short hairpin RNAs (shRNAs) targeted to non-overlapping regions of Rad21. Quantitative reverse transcriptase-PCR (qRT-PCR) and immunoblotting confirmed Rad21 mRNA (Supplementary Figure S1 To assess whether Rad21 depletion altered self-renewal in vitro, we performed serial replating assays. [23] [24] [25] [26] Through serial replating, Rad21-depleted cells maintained the ability to generate colonyforming units (CFUs) and showed enhanced proliferation (Figures 1d and e ). During the fourth replating, Rad21-depleted colonies were larger and denser than control colonies ( Figure 1f ). Based on recent findings that chronic cohesin depletion in HSPCs causes elevated erythroid potential, 25 we monitored granulocyte/ marcophage (CFU-GM), granulocyte/erythrocyte/monocyte/ megakaryocyte (CFU-GEMM) and erythroid blast-forming unit (CFU-BFU-E) colonies at the end of primary methylcellulose passage. We observed no statistically significant differences between the Rad21-depleted HSPCs compared with controls ( Figure 1g ). From these data, we conclude that Rad21 depletion confers enhanced self-renewal to murine HSPCs in vitro consistent with published studies. [23] [24] [25] [26] One possible explanation for the enhanced self-renewal is that Rad21 depletion selectively depletes lower-order progenitors, thereby enriching for LT-HSCs and ST-HSCs. Thus we monitored the percentages of c-kit-negative/lineage-positive and c-kitpositive/lineage-negative cells and observed no significant differences between the Rad21-depleted and empty vector cells ( Supplementary Figures S2A-C) . Importantly, this assay is not sensitive enough to distinguish between subtypes of higher-order HSPCs (LT-HSCs, ST-HSCs and multipotent progenitors). These data are consistent with previous studies that observed minimal changes in differentiation of cohesin-deficient HSPCs at 1 week during ex vivo culture. 26 Rad21 depletion does not induce aneuploidy Given that patients with germline heterozygous cohesin mutations are not predisposed to aneuploidy, 11, 27 we hypothesized that Rad21 depletion of 50% would not induce aneuploidy. 28 We identified cells in G 0 /G 1 (2N DNA content), S phase (2N-4N), Mitosis (4N) and aneuploid cells (o 2N or 44N) by flow cytometry. In accordance with published studies, 7,23-26 we observed no significant increases in aneuploid cells following Rad21 depletion but did observe enhanced self-renewal evidenced by decreased cells in G 0 /G 1 with increased cells in S and M phases following Rad21 depletion (Supplementary Figure S3 ).
Rad21 depletion causes increased expression of the self-renewal factor Hoxa9
We hypothesized that Rad21 depletion increases self-renewal through alterations in gene expression. Next we isolated mRNA from HSPCs at the end of the primary passage and conducted targeted transcriptome analyses by microarray. Overall, approximately 1000 probes (384 probes UP and 660 DOWN) demonstrated a minimum twofold change following Rad21 depletion, consistent with reduced Rad21 levels causing broad changes in gene expression ( Supplementary Table S5 ). Among genes with a statistically significant change following Rad21 depletion (Figure 2a and Supplementary Table S5 ), we noted an approximately 10-fold increase in the expression of Hoxa9, a homeodomain-containing transcription factor that is overexpressed in about half of human AMLs. HoxA9 expression is associated with a poor prognosis [29] [30] [31] and is known to confer enhanced self-renewal on HSPCs in vivo and in vitro. 32, 33 We reasoned that if Rad21/cohesin negatively regulates Hoxa9, its expression would be elevated rapidly and chronically following Rad21 depletion. We noted a statistically significant increase in Hoxa9 expression within 24 h of Rad21 depletion (Figure 2b ), which was maintained through secondary replatings ( Figure 2c ). Next we reanalyzed microarray data sets in which a 4-hydroxytamoxifen-inducible Hoxa9 expression vector was used 34 (GSE21299) to identify genes activated (Hoxa9-Up) or repressed (Hoxa9-Down) by Hoxa9 overexpression. We analyzed Hoxa9-altered genes using Gene Set Enrichment Analysis to determine whether they demonstrated a statistically significant, concordant difference with the gene lists generated from Rad21depleted HSPCs. 35 We observed a significant concordance with Rad21 depletion (Figure 3a ), specifically that Hoxa9-activated genes were elevated and Hoxa9-repressed genes were repressed following Rad21 depletion. To confirm that a small subset of genes was not driving this phenomenon, we selected the top 100 genes increased or decreased by Hoxa9 overexpression and monitored changes in the same probes after Rad21 depletion. Additionally, we compared our microarray data to a recently published RNA-seq data set in which cohesin subunits (Rad21 and Smc3) were depleted and found that, in all samples, Hoxa9 target genes showed a similar pattern of expression 25 (Figure 3b ). More broadly, we found substantial overlap between our microarray data and previously published RNA-seq data 25 Figure S4) .
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Given the increased self-renewal phenotype, we wondered whether Meis1, which cooperates with Hoxa9 to induce AMLs, was also overexpressed by Rad21 depletion. [36] [37] [38] qRT-PCR analyses did not reveal any differences in Meis1 expression (Supplementary Figure S5 ). Collectively, these data show that Rad21 depletion induces aberrant expression of Hoxa9 and its downstream targets but has no effect on Meis1 expression, which is consistent with the observation that cohesin depletion alone is insufficient to drive leukemic transformation.
Additional HoxA family members exhibit increased expression in Rad21-depleted HSPCs Because the entire Hoxa locus is silenced by polycomb repressive complex 2 (PRC2) during hematopoiesis, 21, 39 we speculated that additional Hoxa factors would exhibit elevated expression. Thus we reanalyzed published RNA-seq data from cohesin-depleted HSPCs 25 and found elevated expression of Hoxa7 and Hoxa9, with smaller changes in other HoxA genes (Supplementary Figure S6A ). We confirmed these data by qRT-PCR and included Hoxb4 as a negative control as it was unchanged following cohesin depletion 25 (Supplementary Figure S6B) . Given the known role of the cohesin complex in modulating the expression of genes within chromatin domains, 40, 41 these data imply that Rad21 is required to repress the chromatin domain containing Hoxa7 and Hoxa9.
AML patients with cohesin mutations have elevated levels of Hoxa7 and Hoxa9
Given changes in Hoxa7 and Hoxa9 expression following cohesin depletion, we hypothesized that AML patients harboring cohesin mutations would express higher levels of both Hoxa7 and Hoxa9 compared with AML patients lacking cohesin mutations. Next we reanalyzed transcriptome data sets from The Cancer Genome Atlas, of which 47% were karyotypically normal. 3, 4 Among patients with (25) or without (172) cohesin mutations (SMC1A, SMC3, STAG2 or RAD21), we observed a statistically significant increase in both HOXA7 and HOXA9 expression in cohesin-mutated AML (Figure 3c ). Consistent with a multiple hit model of AML, cohesin mutations co-occur most frequently with mutations in NPM1 (P-value 6.32 × 10 − 3 ). 3, 4 Depletion of Hoxa7 or Hoxa9 diminshes HSPC self-renewal: Given the elevated expression of Hoxa7 and Hoxa9, we wondered whether depletion of either of these two factors could rescue the enhanced self-renewal phenotype elicited by Rad21 depletion. Thus we transduced HSPCs with empty vector alone, Rad21-shRNAs alone or Rad21-shRNAs combined with Hoxa9-or Hoxa7-shRNAs. At the end of primary methylcellulose plating, we observed fewer colonies present in the Rad21/Hoxa7 or Rad21/ Hoxa9 co-depleted cultures ( Supplementary Figures S7A and S8A ). This reduction in colony number was associated with overall reduced cell numbers, and the phenotype was maintained in secondary platings (Supplementary Figures S7B-E and S8B-E). These data are consistent with previously published reports highlighting a role of Hoxa7 and Hoxa9 in regulating HSPC selfrenewal. 37, [42] [43] [44] Importantly, depletion of Hoxa7 or Hoxa9 alone ( Supplementary Figures S9A and B ) diminishes HSPC self-renewal ( Supplementary Figures S9C-G) . Thus both Hoxa7 and Hoxa9 are required for HSPC self-renewal, and their effects following Rad21 depletion are not a form of epistasis.
Rad21 cooperates with PRC2 to repress target gene expression
Previous studies have shown that Hoxa7 and Hoxa9 expression are repressed by the PRC2 complex 39, 45 and selectively induced in myeloid-and erythroid-committed progenitor cells by removal of its associated histone mark H3K27me3. 46, 47 To identify pathways altered by Rad21 depletion in an unbiased manner, we performed Gene Set Enrichment Analysis and screened 3395 different pathways (gene sets). Each curated gene set was generated by perturbing a biological system with different chemical, RNAi or genetic means. We narrowed the list ( Supplementary Table S6 ) by focusing on gene sets derived from hematopoietic tissues and noted an upregulation of 38 genes repressed by Ezh2 (Figure 4a ), the catalytic subunit of the PRC2 complex. 48 We confirmed this derepression by a differential expression analysis (Figure 4b ).
Collectively, these data imply that Rad21 depletion causes derepression of PRC2 target genes. The derepression of a large number of its target genes suggests either reduced PRC2 levels or impaired activity. To investigate the former, we performed immunoblotting for two members of the PRC2 complex and observed no significant difference in the levels of Ezh2 or Suz12 (Figures 4c-e ). Next we assessed whether global levels of histone H3K27me3 were altered by Rad21 depletion. Following Rad21 depletion, we observed an approximately 40-50% reduction in histone H3K27me3 levels (Figures 4c and f) . From these data, we conclude that Rad21 depletion reduces levels of the repressive mark H3K27me3 without disrupting PRC2 expression.
Cohesin and PRC2 complexes interact in murine myeloid cells Given our results, we hypothesized that cohesin and PRC2 interact to mediate epigenetic silencing. First, we reanalyzed a published proteomics study that characterized binding partners of the PRC2 complex 49 and noted that the core PRC2 subunit Eed interacted with Rad21 in two murine cell types (Supplementary Figure S10 ). Next we performed co-immunoprecipitation experiments using lysates from immortalized murine myeloblast cells (32D cells). We observed interactions between members of the cohesin and PRC2 complexes and could identify these interactions by immunoprecipitating either complex (Figure 5a ). Members of the cohesin and PRC2 complexes are shown in Figure 5b for reference. Whether the interactions observed represent direct or indirect association between the two complexes will require additional studies.
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Rad21 mediates PRC2 recruitment to the Hoxa9 locus and deposition of H3K27me3
Given that Rad21 and PRC2 interact in myeloid cells and that Hoxa genes are silenced by PRC2, 30, 45 we hypothesized that cohesin would be bound near the Hoxa7 and Hoxa9 locus. Using data from both the ENCODE projects, we identified Rad21/RAD21 occupancy between the Hoxa7/HOXA7 and Hoxa9/HOXA9 genes at a Ctcf/ CTCF-binding site. The entire Hoxa/HOXA locus exhibits high levels of enrichment of the repressive histone mark H3K27me3 consistent with PRC2-mediated silencing. These patterns were observed in both mouse (Supplementary Figure S11) and human (Supplementary Figure S12) hematopoietic and nonhematopoietic cell lines. The proximity of a cohesin:CTCF site was intriguing; in other contexts, CTCF mediates gene silencing and in the Hoxa cluster facilitates PRC2 targeting. 17, 21, 22 Next we hypothesized that Rad21 depletion induces Hoxa7 and Hoxa9 expression through loss of H3K27me3. Chromatin immunoprecipitation analyses revealed a significant reduction in H3K27me3 at the promoters of both Hoxa7 and Hoxa9 following Rad21 depletion (Figure 6a ). In summary, these data demonstrate that Rad21 facilitates PRC2-mediated silencing of Hoxa7 and Hoxa9 (Figure 6b) . Given the colocalization of cohesin, PRC2 and CTCF at the Hoxa locus ( Supplementary Figures S11 and S12) , we wondered whether depletion of Ctcf in HSPCs would phenocopy the enhanced self-renewal observed following Rad21 depletion. Ctcf depletion had minimal effect on Hoxa7 (Supplementary Figure S13B) or Hoxa9 (Supplementary Figure S13C) expression. The lack of elevated Hoxa7 and Hoxa9 expression was accompanied by a reduced number of CFUs and cell number ( Supplementary Figures S13D and E) . These data suggest that, although CTCF likely has a role in regulating PRC2 and cohesin occupancy at the Hoxa locus, its functions are so diverse that its depletion is not tolerated by HSPCs.
DISCUSSION
AML is a complex myeloid malignancy hallmarked by genetic heterogeneity, and as with most cancers, multiple cooperating mutations are involved in oncogenic transformation. This implies that different genetic mutations disrupt similar pathways inducing a shared phenotype such as enhanced self-renewal. In this study, we focused on cohesin mutations, which are frequently observed in AML. Recent studies have shown that reduced cohesin promotes hematopoietic self-renewal and, when combined with FLT3-ITD, causes 100% penetrant AML. [23] [24] [25] [26] In addition, these studies observed changes in chromatin accessibility following cohesin depletion. In one study, genes displaying increased chromatin accessibility around their transcription start site demonstrated increased occupancy by transcription factors critical to self-renewal, such as Gata2, Erg and Runx1. 23 Our study lends further mechanistic insight in that the PRC2 histone mark H3K27me3 classically promotes recruitment of the PRC1 complex, which mediates polynucleosome compaction. 50, 51 Thus cohesin loss may ultimately impart enhanced self-renewal by preventing proper chromatin compaction around genes that need to be silenced for proper differentiation. One open question is how the cohesin complex is targeted to the Hoxa locus to recruit the PRC2 complex to mediate epigenetic silencing. One possible explanation is that cohesin regulates gene expression by modulating genomic architecture. Key insights into the role of cohesin in regulating gene expression were uncovered with the discovery of a direct interaction between cohesin and the DNA-binding protein CTCF. 17 CTCF has a central role in regulating gene expression at multiple levels, including acting as an insulator to block enhancer:gene interactions or to organize the genome into topologically associated domains (TADs [52] [53] [54] [55] AURKB  CCNB2  TFDP1  NUSAP1  AURKA  SMC2  POLE2  MAD2L1  TOPBP1  ECT2  PPP1CC  TOP2A  RPA3  XPO1  CDCA5  KPNA2  EED  TACC3  SMC4  HAT1  CDCA7  DBF4  PRC1  RBL1  IPO5  RRM1  H2AFZ  AHCY  GMNN  NAP1L1  PRIM1  RFC1  NEK2  MKI67  SETDB1  MCM3 regulating genomic architecture, specifically establishment of TADs. Interestingly, seminal studies from the laboratory of Merkenschlager and Odom 19 demonstrated that homozygous deletion of Rad21 in non-cycling thymocytes does not alter TAD architecture but rather disrupts long-range interactions within TAD compartments (sub-TADs 41 ). The authors found that TAD architecture overall remained intact but that cohesin loss resulted in compression of the dynamic range of gene expression through loss of sub-TAD interactions. This is interesting because other studies have shown that the Hoxa cluster is regulated in a tissuespecific manner by CTCF and cis-regulatory elements located within sub-TADs surrounding the Hoxa locus, which ultimately results in PRC2-mediated gene silencing. 21, [56] [57] [58] Our data supports a model whereby cohesin is essential for proper PRC2 recruitment and inhibition of Hoxa7 and Hoxa9 expression, which may be the result of a sub-TAD interaction dependent upon cohesin. Unlike the results of Seitan et al., 41 we did not see broad increases across all Hox clusters, as would be predicted if all sub-TAD interactions were disrupted. The discrepancy is likely secondary to differences in the level of cohesin loss, specifically our use of an approximately 50% reduction in Rad21 levels versus complete deletion of Rad21. Alternatively, it may be secondary to our use of cycling bone marrow cells, as opposed to non-cycling thymocytes. Importantly, this raises the intriguing hypothesis that some cohesin-dependent chromatin interactions require a higher level of cohesin than others.
Our data demonstrate an interaction between the cohesin and PRC2 complexes, disruption of which increases the expression of the self-renewal factor Hoxa9. Determining whether the interactions between the cohesin and PRC2 complexes are direct or indirect will require additional studies. Modulators of this pathway could provide possible therapeutic targets for patients with cohesin-mutated AML. Hoxa9 expression has been shown to be, in part, activated by di-or tri-methylation of histone H3 on lysine 79 (H3K79me2/me3) catalyzed by Dot1l, which is blocked by PRC2 activity. [59] [60] [61] Dot1l inhibitors are already in clinical trials for mixedlineage leukemia-rearranged AML; therefore, these could provide a possible therapeutic approach that could reverse the aberrant expression of Hoxa genes in cohesin-mutated AML. Whether or not these histone marks are altered upon Rad21/cohesin depletion remains unknown but provide testable hypotheses to identify therapeutic targets for patients with cohesin-mutated AML. 
